# China NMPA Product Recall - Biological acetabular cup system

Source: https://www.keypedia.com/records/china_product_recall/depuy-orthopaedics-inc/fad0465d-568c-49ce-89b5-87f2cd219eaf
Source feed: China

> China NMPA product recall for Biological acetabular cup system by DePuy Orthopaedics, Inc. published January 13, 2017. Recall level: . The National Medical Products Administration (NMPA) in China announced a voluntary recall initiated 

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: DePuy Orthopaedics, Inc. is recalling its biological acetabular cup system.
- Company Name: DePuy Orthopaedics, Inc.
- Publication Date: 2017-01-13
- Product Name: Biological acetabular cup system
- Recall Reason: The biological acetabular cup system was manufactured by four different companies. Ten biological acetabular cup systems manufactured by a company not registered in Japan were imported into Japan and distributed to hospitals.
- Discovering Company: Johnson & Johnson (Shanghai) Medical Devices Co., Ltd.
- Manufacturing Company: DePuy Orthopaedics, Inc.
- Summary: The National Medical Products Administration (NMPA) in China announced a voluntary recall initiated by Johnson & Johnson (Shanghai) Medical Devices Co., Ltd., concerning the DePuy Orthopaedics, Inc. Biological Acetabular Cup System. The recall report, dated January 4, 2017, indicated that 10 units of this system, imported into Japan, were found to have been manufactured by an unregistered company. While DePuy Orthopaedics is the primary manufacturer, Johnson & Johnson (Shanghai) served as the responsible entity for the product in China. The affected product, registered under NMPA Certificate No. 20153460710 and intended for uncemented hip replacement, was subject to recall due to this manufacturing non-compliance. These specific problematic batches were distributed exclusively in Japan. Crucially, Johnson & Johnson confirmed that none of the affected products were imported into or sold within the Chinese market. Consequently, no direct corrective actions were necessitated for products within China. The NMPA's directive following this report was for provincial Food and Drug Administrations to strengthen their supervision and management of similar medical devices. This proactive measure reinforces regulatory vigilance to prevent the entry and distribution of non-compliant products, thereby upholding public health standards within China.

Company: https://www.keypedia.com/companies/depuy-orthopaedics-inc/abe8ff95-754c-4e38-898b-9df32f104a7a